1. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. Brussels: European Parliament; 2011.
2. Vogler S, Lepuschütz L, Schneider P, Stühlinger V. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. Luxembourg: Gesundheit Österreich Forschungs- und Planungs GmbH; Publications Office of the European Commission; 2016.
3. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.
4. Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Brussels: European Commission, Directorate-General for Economics and Financial Afairs; 2012.
5. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15):1044–8.